This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A year after study results were initially reported, the antibody–drug conjugate trastuzumab deruxtecan continues to show strong activity in patients with advanced HER2-positive breast cancer: In a phase II trial, the agent elicited a high overall response rate and long median progression-free survival—as well as early, but promising, overall survival results.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on January 5, 2021
doi: 10.1158/2159-8290.CD-NB2020-121
More Data, More Benefit with T-DXd in Breast Cancer
Jump to section
Advertisement